Skip to main content
Premium Trial:

Request an Annual Quote

DeCode CEO to Sell Up to 400,000 Shares in Next Year

NEW YORK, July 2 (GenomeWeb News) -Kari Stefansson, CEO of DeCode Genetics, will sell up to 400,000 shares of DeCode's common stock in the next year, or 12 percent of his holdings, under a pre-arranged plan that follows US Securities and Exchange Commission regulations, the company said today.


At today's share price, Stefansson would net about $3.4 million from the transactions.


Under the plan, Stefansson has authorized a broker to sell the shares on his behalf. The move is designed to diversify Stefansson's investments, according to the Reykjavik, Iceland-based company.


The sales are being made pursuant to rule 10b5-1 of the US Securities and Exchange Act of 1934, which allows company insiders to establish pre-arranged stock trading plans not based on inside information.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.